[
  {
    "ts": null,
    "headline": "Tracking Jeremy Grantham's GMO Capital Portfolio - Q2 2025 Update",
    "summary": "GMOâs 13F portfolio grew to $33.23B in Q2 2025, with Microsoft, Meta, Alphabet, Oracle, and Apple as top holdings. Read more about the portfolio here.",
    "url": "https://finnhub.io/api/news?id=1752da494c03f4d1c83d55ee99d4a662014fa49c4d61c67a181e3e504c898d52",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755726539,
      "headline": "Tracking Jeremy Grantham's GMO Capital Portfolio - Q2 2025 Update",
      "id": 136449150,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/186805810/image_186805810.jpg?io=getty-c-w1536",
      "related": "ABT",
      "source": "SeekingAlpha",
      "summary": "GMOâs 13F portfolio grew to $33.23B in Q2 2025, with Microsoft, Meta, Alphabet, Oracle, and Apple as top holdings. Read more about the portfolio here.",
      "url": "https://finnhub.io/api/news?id=1752da494c03f4d1c83d55ee99d4a662014fa49c4d61c67a181e3e504c898d52"
    }
  },
  {
    "ts": null,
    "headline": "DexCom Expands Access and Innovation While Balancing Headwinds",
    "summary": "DXCM grows on type 2 access, Stelo adoption, and new sensor launches, but faces margin pressures, competition and leadership transition.",
    "url": "https://finnhub.io/api/news?id=99e5825bb5552d6e09a7e288b74e3bc8f3dcbd20087d42095e94e05cc679ff4a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755703200,
      "headline": "DexCom Expands Access and Innovation While Balancing Headwinds",
      "id": 136439276,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "DXCM grows on type 2 access, Stelo adoption, and new sensor launches, but faces margin pressures, competition and leadership transition.",
      "url": "https://finnhub.io/api/news?id=99e5825bb5552d6e09a7e288b74e3bc8f3dcbd20087d42095e94e05cc679ff4a"
    }
  },
  {
    "ts": null,
    "headline": "GEHC Positioned for Growth With AI, Global Expansion and Margins",
    "summary": "GE HealthCare's Q2 results highlight revenue growth, AI-driven innovation, and global expansion with margin gains and strong demand.",
    "url": "https://finnhub.io/api/news?id=ae58255428997ac439a34346591dfff0cdf9bfd57a4741b2327d97370c59df3e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755703200,
      "headline": "GEHC Positioned for Growth With AI, Global Expansion and Margins",
      "id": 136439379,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "GE HealthCare's Q2 results highlight revenue growth, AI-driven innovation, and global expansion with margin gains and strong demand.",
      "url": "https://finnhub.io/api/news?id=ae58255428997ac439a34346591dfff0cdf9bfd57a4741b2327d97370c59df3e"
    }
  },
  {
    "ts": null,
    "headline": "Should You Invest in Abbott (ABT) Based on Bullish Wall Street Views?",
    "summary": "Based on the average brokerage recommendation (ABR), Abbott (ABT) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?",
    "url": "https://finnhub.io/api/news?id=74aa7470e2f89c2bd3cbadbbd5e1f46abe76c906f7a997c7e219ced6c1d4e799",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755696602,
      "headline": "Should You Invest in Abbott (ABT) Based on Bullish Wall Street Views?",
      "id": 136437532,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Based on the average brokerage recommendation (ABR), Abbott (ABT) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?",
      "url": "https://finnhub.io/api/news?id=74aa7470e2f89c2bd3cbadbbd5e1f46abe76c906f7a997c7e219ced6c1d4e799"
    }
  },
  {
    "ts": null,
    "headline": "Q2 Earnings Highlights: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks",
    "summary": "Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at AbbVie (NYSE:ABBV) and its peers.",
    "url": "https://finnhub.io/api/news?id=68cef88636aaa7fc0cd9dfec94726e6c9ebba7d704bf8df676a48599fc87c1fb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755660994,
      "headline": "Q2 Earnings Highlights: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks",
      "id": 136437477,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at AbbVie (NYSE:ABBV) and its peers.",
      "url": "https://finnhub.io/api/news?id=68cef88636aaa7fc0cd9dfec94726e6c9ebba7d704bf8df676a48599fc87c1fb"
    }
  }
]